---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-044409"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:28:19.110754+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics reports Q3 2024 revenue $15.4M; net loss narrows to $0.35/share

## Summary
- Revenue rose to $15.4M (up 39% YoY) driven by an $8M Biogen milestone and $2.9M from Betta license.
- Net loss improved to $24.7M from $27.0M YoY; diluted EPS of -$0.35 vs -$0.55.
- Cash, equivalents and marketable securities $284.4M at Sep 30; expected runway into 2027.
- Cemsidomide Phase 1/2 trial enrolling; MM and NHL data to be presented at ASH Dec 2024.
- Appointed Paige Mahaney as Chief Scientific Officer; delivered second Biogen development candidate.

## SEC filing metadata
- accession: 0001628280-24-044409
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/0001628280-24-044409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/cccc-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-044409
- JSON: https://secwatch.observer/filing/0001628280-24-044409.json
- Plain text: https://secwatch.observer/filing/0001628280-24-044409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.